Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
Want to see ENLV full AI Analyst Report?
Top Page
Enlivex
(NASDAQ:ENLV)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.68
▼(-21.40% Downside)
Action:Reiterated
Date:04/14/26
The score is primarily constrained by weak financial performance—minimal revenue, ongoing operating losses, and continued cash burn—despite low leverage. Technicals also weigh on the rating as the stock trades below major moving averages with negative MACD. Valuation appears optically cheap due to the very low P/E, but that support is limited given questions about the sustainability of the reported earnings.
Positive Factors
Low financial leverage
Minimal debt reduces bankruptcy risk and preserves financing optionality for a clinical-stage biotech. Low leverage supports the company’s ability to fund R&D or absorb volatility without high interest burdens, a durable advantage during multi-year clinical development cycles.
Negative Factors
Effectively zero operating revenue
As a clinical-stage company with no recurring product revenue, Enlivex remains dependent on trial success for sustainable cash generation. Persistent absence of operating sales means long lead times to profitability and continued funding needs until commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Minimal debt reduces bankruptcy risk and preserves financing optionality for a clinical-stage biotech. Low leverage supports the company’s ability to fund R&D or absorb volatility without high interest burdens, a durable advantage during multi-year clinical development cycles.
Read all positive factors
Enlivex (ENLV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$165.53M
Dividend YieldN/A
Average Volume (3M)182.02K
Price to Earnings (P/E)<0.1
Beta (1Y)0.52
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees71
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)27.02
Shares Outstanding237,381,500
10 Day Avg. Volume216,695
30 Day Avg. Volume182,016
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-47.46
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$20.00Price Target Upside2225.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Enlivex Business Overview & Revenue Model
Company Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical tria...
How the Company Makes Money
null...
Enlivex Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -332.00K | -545.00K | -835.00K | -777.00K | -546.00K |
| EBITDA | -14.67M | -14.47M | -28.22M | -25.02M | -18.74M |
| Net Income | 1.24B | -15.01M | -29.07M | -31.06M | -14.47M |
Balance Sheet | |||||
| Total Assets | 2.33B | 27.69M | 36.83M | 67.64M | 95.15M |
| Cash, Cash Equivalents and Short-Term Investments | 5.87M | 23.61M | 27.32M | 48.12M | 84.13M |
| Total Debt | 641.00K | 534.00K | 1.03M | 4.85M | 617.00K |
| Total Liabilities | 392.05M | 4.10M | 6.75M | 10.80M | 10.11M |
| Stockholders Equity | 1.93B | 23.59M | 30.08M | 56.84M | 85.04M |
Cash Flow | |||||
| Free Cash Flow | -10.48M | -13.11M | -23.76M | -32.08M | -19.17M |
| Operating Cash Flow | -10.42M | -13.01M | -23.52M | -23.95M | -17.54M |
| Investing Cash Flow | -1.32M | 9.06M | -25.97M | 62.52M | -38.41M |
| Financing Cash Flow | 10.38M | 6.45M | 360.00K | 150.00K | 60.98M |
Enlivex Technical Analysis
Negative
0.86
Price Trends
0.91
Negative
0.96
Negative
1.02
Negative
Market Momentum
-0.06
Positive
30.82
Neutral
8.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENLV, the sentiment is Negative. The current price of 0.86 is above the 20-day moving average (MA) of 0.80, below the 50-day MA of 0.91, and below the 200-day MA of 1.02, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 30.82 is Neutral, neither overbought nor oversold. The STOCH value of 8.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENLV.
Enlivex Risk Analysis
Enlivex disclosed 70 risk factors in its most recent earnings report. Enlivex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enlivex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $31.61M | -2.20 | 763.44% | ― | ― | ― | |
44 Neutral | $165.53M | <0.01 | 248.08% | ― | ― | ― | |
42 Neutral | $3.96M | -0.46 | -68.21% | ― | ― | ― | |
42 Neutral | $16.42M | -0.83 | -135.04% | ― | ― | 42.29% |
* Healthcare Sector Average
ENLV
Enlivex
0.70
-0.28
-28.09%
DARE
Daré Bioscience
2.25
-0.64
-22.15%
AKTX
Akari Therapeutics
3.74
-45.86
-92.46%
PASG
Passage Bio
5.08
-0.94
-15.61%
Enlivex Corporate Events
Enlivex Doses First U.S. Patient in Phase 2b Allocetra Trial for Knee Osteoarthritis
May 18, 2026
On May 18, 2026, Enlivex announced it had dosed the first patient at a U.S. clinical site in its global Phase 2b trial of Allocetra for moderate-to-severe age-related primary knee osteoarthritis, following FDA IND clearance in March and Danish reg...
Enlivex Faces Nasdaq Minimum Bid Price Deficiency After Shares Fall Below $1 Threshold
May 15, 2026
Enlivex Ltd. is a Nasdaq-listed quality longevity company based in Israel that is advancing Allocetra™, a clinical-stage immunotherapy for aging-related inflammatory conditions, primarily age-related osteoarthritis. The company also operates...
Enlivex Secures Danish Approval for Global Phase 2b Trial of Allocetra in Knee Osteoarthritis
Apr 21, 2026
On April 21, 2026, Enlivex announced it received Clinical Trial Application approval from the Danish Medicines Agency to conduct a Phase 2b trial of Allocetra in patients with moderate-to-severe age-related primary knee osteoarthritis. This second...
Enlivex Shares Tokenized on Ondo Global Markets to Expand Global Digital Investor Access
Apr 8, 2026
On April 8, 2026, Enlivex announced that Ondo Finance has launched ENLVon, a tokenized representation of Enlivex’s ordinary shares on Ondo’s Global Markets platform. The move positions Enlivex at the junction of traditional capital mar...
Enlivex Highlights Rain’s AI Agent Launch and $5 Million Grant Program to Expand Prediction Markets
Mar 26, 2026
On March 26, 2026, Enlivex reported that the Rain Foundation, which oversees the decentralized Rain prediction markets protocol in which Enlivex holds a significant RAIN token position, launched an AI agent‑ready interface and a $5 million g...
Enlivex Posts $1.23 Billion Profit for 2025 on Treasury Asset Gains
Mar 25, 2026
Enlivex Ltd., a quality longevity company listed on Nasdaq and headquartered in Nes‑Ziona, Israel, combines development of its Allocetra™ immunotherapy for age‑related inflammatory conditions with a treasury strategy tied to the ...
Enlivex Secures $21 Million Convertible Debt, Expands RAIN Token Holdings and Launches $20 Million Buyback
Mar 24, 2026
On March 23, 2026, Enlivex completed a $21 million senior secured convertible note financing with The Lind Partners, yielding about $18.7 million in net proceeds and convertible into ordinary shares at $2.69175, a hefty premium to its recent Nasda...
Enlivex Wins FDA IND Clearance for Global Phase 2b Trial of Allocetra in Knee Osteoarthritis
Mar 23, 2026
On March 23, 2026, Enlivex announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for Allocetra to treat moderate-to-severe age-related primary knee osteoarthritis. The clearance, based on encouraging...
Enlivex Rebrands as Enlivex Ltd. Following Shareholder Approval
Feb 23, 2026
On February 3, 2026, Enlivex Therapeutics Ltd. held an Extraordinary General Meeting of Shareholders in Israel, where investors approved a proposal to change the company’s name to Enlivex Ltd. The change underscores a streamlining of the cor...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.